Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)

被引：0
|
作者：
Morice, Alyn [1 ]
Birring, Surinder [2 ]
Dicpinigaitis, Peter [3 ]
McGarvey, Lorcan
Pavord, Ian [4 ]
Smith, Jaclyn [5 ]
La Rosa, Carmen [6 ]
Li, Qing [6 ]
Nguyen, Allison Martin [6 ]
Schelfhout, Jonathan [6 ]
Tzontcheva, Anjela [6 ]
Muccino, David [6 ]
机构：
[1] Univ Hull, Kingston Upon Hull, N Humberside, England
[2] Kings Coll London, London, England
[3] Jack D Weiler Hosp, Bronx, NY USA
[4] Univ Oxford, Oxford, England
[5] Univ Manchester, Manchester, Lancs, England
[6] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2021年 / 147卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
188
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [31] Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist
    Birring, Surinder S.
    Mcgarvey, Lorcan
    Smith, Jaclyn
    Morice, Alyn
    Sher, Mandel
    Wu, Wen-Chi
    Xu, Zhi Jin
    Nguyen, Allison M.
    Schelfhout, Jonathan
    Muccino, David
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [32] Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough
    Gupta, Pranav
    Hussain, Azher
    Ford, Anthony P.
    Smith, Steven
    Nussbaum, Jesse C.
    Stoch, Aubrey
    Iwamoto, Marian
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1054 - 1067
  • [33] CONSISTENCY OF IMPROVEMENT WITH GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN CHRONIC COUGH PATIENTS DURING WAKING HOURS AND OVER 24 HOURS
    Mehta, Anish
    Morice, Alyn
    Birring, Surinder
    McGarvey, Lorcan
    Sher, Mandel
    Muccino, David
    Smith, Jacky
    CHEST, 2019, 156 (04) : 1576A - 1577A
  • [34] Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
    Smith, Jaclyn A.
    Kitt, Michael M.
    Morice, Alyn H.
    Birring, Surinder S.
    McGarvey, Lorcan P.
    Sher, Mandel R.
    Li, Yu-Ping
    Wu, Wen-Chi
    Xu, Zhi Jin
    Muccino, David R.
    Ford, Anthony P.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (08): : 775 - 785
  • [35] Treatment of chronic cough: P2X3 receptor antagonists and beyond
    Sykes, Dominic L.
    Zhang, Mengru
    Morice, Alyn H.
    PHARMACOLOGY & THERAPEUTICS, 2022, 237
  • [36] Potential applications of P2X3 receptor antagonists in the treatment of refractory cough
    Yi, Baiyi
    Wang, Shengyuan
    Li, Wanzhen
    Xu, Xianghuai
    Yu, Li
    RESPIRATORY MEDICINE, 2023, 217
  • [37] Mk-7264, A P2x3 Receptor Antagonist, Reduces Cough Frequency In Patients With Refractory Chronic Cough: Results From A Randomized, Controlled, Phase 2b Clinical Trial
    Smith, J. A.
    Kitt, M. M.
    Morice, A. H.
    Birring, S. S.
    McGarvey, L. P.
    Sher, M. R.
    Ford, A. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [38] Efficacy of gefapixant, a P2X3 antagonist, for lung cancer-related cough: a case report
    Ishiura, Yoshihisa
    Nomura, Shosaku
    Ishii, Yuka
    Imai, Kai
    Sawai, Yusuke
    Tamaki, Takeshi
    Shimizu, Toshiki
    Miyashita, Naoyuki
    Ito, Tomoki
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (08)
  • [39] Prevalence And Characterization of Cough-Related Urinary Incontinence in A Refractory Chronic Cough Population Enrolled in A Phase 2b Trial of The P2X3 Antagonist, Camlipixant
    Mcgarvey, Lorcan
    Birring, Surinder S.
    Dicpinigaitis, Peter
    Smith, Jaclyn
    Iyer, Vivek N.
    Lanouette, Sylvain
    Yang, Ronghua
    Harvey, Laurent
    Garin, Margaret
    Bonuccelli, Catherine M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [40] BENEFITS OBSERVED WITH PATIENT-REPORTED OUTCOMES IN A PHASE 2B CLINICAL TRIAL OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST IN CHRONIC COUGH
    Mehta, Anish
    Birring, Surinder
    McGarvey, Lorcan
    Smith, Jacky
    Morice, Alyn
    Sher, Mandel
    Schelfhout, Jonathan
    Muccino, David
    CHEST, 2019, 156 (04) : 1782A - 1783A
12345